Holen Sie sich die Stockscreener-App
55.49
3.78%
2.2527
Schlusskurs vom Vortag:
$53.24
Offen:
$53.52
24-Stunden-Volumen:
239.62K
Relative Volume:
0.17
Marktkapitalisierung:
$5.27B
Einnahmen:
$4.72M
Nettoeinkommen (Verlust:
$-277.91M
KGV:
-14.88
EPS:
-3.73
Netto-Cashflow:
$-203.56M
1W Leistung:
+18.23%
1M Leistung:
+15.34%
6M Leistung:
+70.89%
1J Leistung:
+13.92%
1-Tages-Spanne:
$53.52
$55.89
1-Wochen-Bereich:
$43.40
$57.99
52-Wochen-Spanne:
$24.10
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Firmenname
Crinetics Pharmaceuticals Inc
Sektor
Branche
Telefon
858-450-6464
Adresse
6055 LUSK BLVD., SAN DIEGO, CA
Vergleichen Sie CRNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
55.52 | 5.05B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.36 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.17 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.36 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.32 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | Goldman | Neutral |
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-11 | Eingeleitet | TD Cowen | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-01-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-12-21 | Eingeleitet | Jefferies | Hold |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-24 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Eingeleitet | ROTH Capital | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-13 | Eingeleitet | JP Morgan | Neutral |
| 2018-08-13 | Eingeleitet | Leerink Partners | Outperform |
| 2018-08-13 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Crinetics Pharmaceuticals prices offering at $45.95 per share - MSN
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Strong Share Price Momentum - Sahm
What risks investors should watch in Crinetics Pharmaceuticals Inc. stock2025 Trade Ideas & Stepwise Trade Execution Plans - ulpravda.ru
Is Crinetics Pharmaceuticals Inc. stock overvalued by current metricsWeekly Trend Report & High Conviction Trade Alerts - ulpravda.ru
Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersTrade Volume Summary & Technical Pattern Alert System - ulpravda.ru
Gains Report: Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersJuly 2025 Spike Watch & Safe Capital Preservation Plans - ulpravda.ru
How risky is Crinetics Pharmaceuticals Inc. stock nowJuly 2025 Outlook & Risk Controlled Stock Pick Alerts - ulpravda.ru
Crinetics Pharmaceuticals (CRNX): Analyst Updates on Price Targe - GuruFocus
Crinetics stock price target lowered to $105 by Citizens on endocrinologist survey - Investing.com UK
US Market Wrap: Will Crinetics Pharmaceuticals Inc 6Z4 stock issue positive guidance2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Crinetics (CRNX) Sees Significant Stock Price Increase - GuruFocus
Crinetics Pharma CCO Kalofonos sells $137,500 in shares By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals’ Positive Trial Results and Stock Target Uplift Spark Optimism - StocksToTrade
Crinetics Announces Major Public Offering to Fund Growth - TipRanks
Crinetics’ Stocks Surge: Promising Future or Mirage? - timothysykes.com
Crinetics Pharmaceuticals Announces Public Offering of Common Stock - TradingView — Track All Markets
Crinetics Pharmaceuticals announces $350M proposed public offering - MSN
Crinetics Shares Rise After Pricing $350 Million Stock Offering - MarketScreener
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial - Asianet Newsable
Crinetics Pharmaceuticals’ Stock Surges after Positive Trial Results and Analyst Boosts - timothysykes.com
Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits - TechStock²
Crinetics (CRNX) Stock Soars Over 12% Amid Market Activity - GuruFocus
Why Crinetics Pharmaceuticals Shares Are Sinking Today - TipRanks
Crinetics Pharma climbs after $350 mln stock sale - TradingView — Track All Markets
Crinetics Pharmaceuticals (CRNX) Stock Analysis: A Deep Dive Into 71% Upside Potential - DirectorsTalk Interviews
Crinetics Prices $350 Million Stock Offering - MarketScreener
Crinetics Pharmaceuticals prices public offering at $45.95 per share - Investing.com India
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock - The Manila Times
Crinetics Pharmaceuticals prices public offering at $45.95 per share By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals Prices Public Offering of 7.62 Million Shares at $45.95 Each, Anticipating $350 Million in Proceeds - Quiver Quantitative
Crinetics Pharmaceuticals prices public offering of 7.6 million shares at $45.95 each - MarketScreener
Crinetics Prices 7.62M Share Offering at $45.95, Raising $350M - Intellectia AI
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 8.2%Here's What Happened - MarketBeat
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Exact Sciences (EXAS) - The Globe and Mail
CRNX Stock: Morgan Stanley Raises Price Target to $80 | CRNX Sto - GuruFocus
Morgan Stanley Increases Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $80.00 - MarketBeat
Early PALSONIFY Launch and Atumelnant Data Might Change The Case For Investing In Crinetics (CRNX) - simplywall.st
Crinetics Pharmaceuticals shares down 6.4% after announcing $350 million stock offering - MarketScreener
Crinetics stock outperforms with strong Palsonify sales, Oppenheimer reiterates $87 target - Investing.com Nigeria
Crinetics stock maintains Buy rating at H.C. Wainwright on strong CAH data - Investing.com
Crinetics Pharma ticks down after announcing $350 mln stock offering - TradingView — Track All Markets
Crinetics Pharmaceuticals plans $350 million stock offering By Investing.com - Investing.com Nigeria
Crinetics reports over $5 million in Q4 revenue from acromegaly drug - Investing.com Nigeria
Crinetics Pharmaceuticals stock hits 52-week high at 55.23 USD - Investing.com
Crinetics Buy Rating: Derisked Atumelnant CAH Program and Outperforming Palsonify Launch Signal Undervalued Shares - TipRanks
Crinetics Pharmaceuticals Stock: Biotech Optimism Meets Volatile Reality - AD HOC NEWS
Crinetics shares jump on robust PALSONIFY uptake and encouraging trial results - MSN
Crinetics stock soars after strong PALSONIFY launch and positive trial data - Investing.com
Crinetics plans $350 mln public share offering - MSN
Crinetics Reports Strong Palsonify Launch To Date, Positive Phase II CAH Data - Citeline News & Insights
Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Crinetics Pharmaceuticals Inc-Aktie (CRNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kalofonos Isabel | Chief Commercial Officer |
Jan 05 '26 |
Sale |
55.00 |
2,500 |
137,500 |
834 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):